Arcutis Biotherapeutics Inc (ARQT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.43B
Last updated: Nov 17, 2026 at 4:33 PM ET
Arcutis Biotherapeutics Inc (ARQT) Statistics
Arcutis Biotherapeutics (ARQT) has a market cap of $3.43B and an enterprise value of $3.51B. Revenue grew 60.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 2.21% above the market cap, as debt exceeds cash.
| Market Cap | $3.43B |
|---|---|
| Enterprise Value | $3.51B |
| Latest price (Nov 17, 2026) | $27.33 |
Key Dates
The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 23, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 7.0x and 14.7x.
| P/E Ratio | 130.1x |
|---|---|
| Forward P/E | 88.2x |
| P/S Ratio | 7.0x |
| Forward P/S | 6.3x |
| P/B Ratio | 14.7x |
| P/TBV Ratio | 15.5x |
| P/OCF Ratio | 57.3x |
Enterprise Valuation
Counting debt and cash, the company is valued at 115.6x EBITDA.
| EV / Earnings | 117.3x |
|---|---|
| EV / Sales | 6.9x |
| EV / EBITDA | 115.6x |
Price Statistics
The stock is up 9.32% over 52 weeks and trades 1.19% below its 50-day average.
| Beta (1Y) | 1.57 |
|---|---|
| 52-Week Change | +9.32% |
| 1-Month Change | -14.30% |
| 3-Month Change | +3.29% |
| 6-Month Change | +40.15% |
| 5-Year Change | +51.42% |
| Total Return (1Y) | +9.32% |
| Total Return (3Y CAGR) | +137.46% |
| Total Return (5Y CAGR) | +7.73% |
| Return vs SPY (1Y) | -11.38% |
| Max Drawdown (1Y) | -37.50% |
| Max Drawdown (3Y) | -42.22% |
| Sharpe Ratio (1Y) | 0.00 |
| Correlation with SPY (1Y) | 0.38 |
| 50-Day Average | $27.66 |
| 200-Day Average | $25.40 |
| 52-Week Range | $19.30 to $34.80 |
| RSI (14 Days) | 45.6 |
| Average Volume (20 Days) | 2.24M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.92x current liabilities, and total debt is 0.45x shareholder equity.
| Current Ratio | 2.92x |
|---|---|
| Quick Ratio | 2.66x |
| Debt / Equity | 0.45x |
| Debt / EBITDA | 3.46x |
| Debt / FCF | 1.83x |
| Interest Coverage | 2.07x |
Returns and Efficiency
Return on invested capital is 7.83% over the last 12 months, against a 5-year average of -26.21%.
| Return on Equity (ROE) | 12.26% |
|---|---|
| Return on Assets (ROA) | 5.70% |
| Return on Invested Capital (ROIC) | 7.83% |
| ROA (5Y Average) | -48.11% |
| ROIC (5Y Average) | -26.21% |
| Asset Turnover | 1.14x |
| Inventory Turnover | 1.06x |
| Receivables Turnover | 3.12x |
| Cash Conversion Cycle | 400 days |
Taxes
Income tax took 2.90% of pretax income over the last 12 months.
| Income Tax (TTM) | $894.00K |
|---|---|
| Effective Tax Rate | 2.90% |
Scores
ARQT has an Altman Z-Score of 6.56, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 6.56 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $508.68M over the last 12 months.
| Revenue | $508.68M |
|---|---|
| Revenue Growth (YoY) | +60.00% |
| Gross Profit | $463.81M |
| Operating Income | $35.16M |
| Pretax Income | $30.80M |
| Net Income | $29.91M |
| Reported EPS (TTM) | $0.21 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 46.52% of the $524.43M in total assets.
| Cash and Equivalents | $33.37M |
|---|---|
| Total Debt | $109.40M |
| Net Debt | $76.03M |
| Net Debt Per Share | $0.58 |
| Working Capital | $331.33M |
| Shareholder Equity | $243.97M |
| Book Value Per Share | $1.86 |
| Tangible Book Value | $230.84M |
| Tangible Book Per Share | $1.76 |
| Total Assets | $524.43M |
| Total Liabilities | $280.46M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $255.00K of capital spending, operating cash flow left $59.71M of free cash flow.
| Operating Cash Flow | $59.96M |
|---|---|
| Capital Expenditures | $255.00K |
| Free Cash Flow | $59.71M |
| FCF Per Share | $0.48 |
| Depreciation and Amortization | $3.13M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 6.91%.
| Gross Margin | 91.18% |
|---|---|
| Operating Margin | 6.91% |
| Pretax Margin | 6.06% |
| Net Margin | 5.88% |
| FCF Margin | 11.74% |
Growth
Revenue grew 367.27% a year over 3 years.
| Revenue Growth (3Y CAGR) | +367.27% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | +20.77% |
| Tangible Book Per Share Growth (2Y CAGR) | +20.41% |
Dividends and Yields
ARQT does not pay a dividend.
| Earnings Yield | 0.77% |
|---|---|
| Buyback Yield | -0.03% |
| Shareholder Yield | -0.03% |
Peer Position
Against 9 similar companies, ARQT has the 8th highest P/S and the highest ROIC.
P/S RatioPeer median 13.1x
ROICPeer median -41.75%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +25.30%
| P/S Ratio | 7.0x vs 13.1x median |
|---|---|
| ROIC | 7.83% vs -41.75% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +60.00% vs +25.30% median |
Analyst Forecast
Consensus estimates put revenue growth at 36.72% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +36.72% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ARQT
What is ARQT's market cap?
Arcutis Biotherapeutics has a market cap of $3.43B. Its enterprise value, which adds debt and subtracts cash, is $3.51B.
What is ARQT's P/E ratio?
Arcutis Biotherapeutics has a trailing P/E ratio of 130.1x and a forward P/E of 88.2x.
How many shares of ARQT are outstanding?
Arcutis Biotherapeutics has 131.01M shares outstanding. The count is up 2.65% from a year earlier.
Does ARQT pay a dividend?
No. Arcutis Biotherapeutics does not pay a dividend.
How much debt does ARQT have?
Arcutis Biotherapeutics has $109.40M of total debt and $33.37M of cash and equivalents, a net debt position of $76.03M.
ARQT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors